Emergent BioSolutions (EBS) Tops Q1 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.06 -3.04%
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.16, $0.23 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $111 million versus the consensus estimate of $101.83 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Phoenix Education Partners (PXED) PT Lowered to $32 at Jefferies
- Alphabet stock jumps as buyers return after selloff
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
